(Q38100519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

review article

0 references

title

Treatment optimization in MS: Canadian MS Working Group updated recommendations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

4

Alexandre Prat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Mark S Freedman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Daniel Selchen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Douglas L Arnold

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Brenda Banwell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Michael Yeung

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

David Morgenthau

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Yves Lapierre

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Canadian Multiple Sclerosis Working Group

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

Canadian Journal of Neurological Sciences

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

307-323

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

The toronto observational study of natalizumab in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Sun exposure and vitamin D are independent risk factors for CNS demyelination

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

The relationship between cognitive deficits and everyday functional activities in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Comparison of the 2- and 6-minute walk test in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

The Prognostic Value of Initial Relapses on the Evolution of Disability in Patients with Relapsing-Remitting Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cognitive impairment after three decades of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Demyelinating events in early multiple sclerosis have inherent severity and recovery

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Disability as an outcome in MS clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Treatment optimization in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Effect of relapses on development of residual deficit in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Neurofilaments as biomarkers in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

SPECIFIC HIGH-AFFINITY RECEPTORS FOR 1,25-DIHYDROXYVITAMIN D3IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS: PRESENCE IN MONOCYTES AND INDUCTION IN T LYMPHOCYTES FOLLOWING ACTIVATION

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Impact of multiple sclerosis relapses on progression diminishes with time

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Relapses in multiple sclerosis are age- and time-dependent

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Fluvoxamine treatment of major depression associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Correlates of cognitive dysfunction in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Quantitative functional measures in MS: what is a reliable change?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Multiple sclerosis relapses: a multivariable analysis of residual disability determinants

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Antidepressant pharmacotherapy of depression associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Risk factors for and management of cognitive dysfunction in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Defining interferon beta response status in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Incidence of acquired demyelination of the CNS in Canadian children

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Assessing changes in relapse rates in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Improving long-term follow-up studies of immunomodulatory therapies

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Therapeutic Effect of Vitamin D3 in Multiple Sclerosis Patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

What happens when natalizumab therapy is stopped?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

How to detect cognitive dysfunction at early stages of multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Effects of acute relapses on neuropsychological status in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Rate of brain atrophy in benign vs early multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Response to interferon beta-1a treatment in African American multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Interpreting patient/informant discrepancies of reported cognitive symptoms in MS.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cognitive impairment in different MS subtypes and clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Therapies for multiple sclerosis: considerations in the pediatric patient

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Clinical scales in progressive MS: predicting long-term disability

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Rapid disease course in African Americans with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Natalizumab dosage suspension: are we helping or hurting?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Contribution of relapses to disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Neuropsychological effects of interferon ?-1a in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Predicting responders to therapies for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Monthly ambient sunlight, infections and relapse rates in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100014244

7 January 2021

10.1017/S0317167100014244

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23603165%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference